GP Pharm - Urology / Oncology Contract Manufacturing Services and Pharmaceutical Platforms

Part of the Lipotec Group, GP Pharm is a pharmaceutical company that undertakes contract manufacturing as well as the pharmaceutical and clinical development of urology and oncology products. We specialise in the manufacture of proprietary controlled release and encapsulated products and take on a wide range of contract manufacturing projects.

We develop and manufacture injectable cytotoxics in solution or freeze-dried forms in a single vial filling line. Our solution or freeze-dried injectable high potency actives are produced across three filling lines (vials, ampoules and pre-filled syringes).

GP Pharm also manufactures high-potency, sterile process encapsulated actives in liposomes and biodegradable polymers.

PROPRIETARY PHARMACEUTICAL TECHNOLOGY

GP Pharm maintains a wide range of pharmaceutical technology platforms that enables the company to remain at the cutting-edge of proprietary urology and oncology product development.

We develop microspheres of lactic-glycolic acid polymers that enable the sustained release of actives as applied for depot formulations of one and three months for leuprolide, triptorelin, goserelin and buserelin.

GP Pharm's work also focuses on the development of liposomes for injection purposes. These contain chromane-6, an innovative proprietary agent that inhibits lipidic peroxidation and thus reduces cardiotoxicity. The company's freeze-dried liposomes provide an alternative oral route for absorption and can be applied to alendronate tromethamine and ferrous sulphate.

Finally, our research into coated bioadhesive microparticles can be applied to LMWH, nimesulide, acyclovir and salmon calcitonin.

PHARMACEUTICAL PRODUCTION AND SALES SERVICES

GP Pharm's headquarters is based in Gavà, close to Barcelona's airport. The company has also established a brand new manufacturing facility for the development of injectable products in Sant Quintí de Mediona, Barcelona. These facilities consist of three independent manufacturing buildings that specialise in finished dosage forms of highly potent APIs including encapsulated and liposomal formulations and cytoxic materials. Our staff take on both contract manufacturing projects and the production of the group's own pharmaceutical lines.

GP Pharm aims to obtain global regulatory approval for the out-licensing of our pharmaceutical products to other markets. With the intention of becoming a major player in local markets for urology and oncology, we also welcome and actively look for products to in-license or co-market through the two new sales networks we plan to establish in the near future. The first will be heavily targeted at urologists while the second will focus more on hospital-based oncologists.